• Follow Us On : 

Jacobson Pharma Forms Joint Venture with Kin Fung Weisen-U


Redaksi | Kamis,31 Oktober 2019 - 12:58:21 WIB
Dibaca: 264 kali 
Jacobson Pharma Forms Joint Venture with Kin Fung Weisen-U

Expands Branded Product Portfolio and Develops New Markets for Gastrointestinal and Respiratory Products

CHINA - 31 October 2019 - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines, announced today that its wholly-owned subsidiary Smiley Sun Limited ("Smiley") has signed a joint venture agreement (the "JV Agreement") with Kin Fung Weisen-U Company Limited ("Kin Fung Weisen-U") to set up a new company (the "Joint Venture") which will be 50%-owned respectively by Smiley and Kin Fung Weisen-U.

The Joint Venture will distribute and sell certain products of Kin Fung Weisen-U, including the well-recognised gastrointestinal drug "Weisen-U" and the popular nasal spray brand "Flucur Nebuliser" to new markets in the Asia Pacific region. It will create an expanded proprietary medicine platform for the Group in support of its regional market development strategy.

The Joint Venture will also explore and develop respective product line extensions for Weisen-U and Po Chai Pills. Furthermore, it will explore and conduct businesses relating to the supply and distribution of non-prescription drugs as well as food/health supplements of the gastrointestinal and respiratory categories in markets worldwide.

In particular, the Joint Venture will have the first right over Smiley and Kin Fung Weisen-U to acquire brands of gastrointestinal and respiratory drugs, and food/health supplements. The Joint Venture will allow the Group to strengthen presence and penetration in the OTC market segment.

With Kin Fung Weisen-U being a long-standing reputable player in the pharmaceutical industry, Jacobson Pharma believes the Joint Venture will give the Company a sound strategic leverage to broaden its portfolio of gastrointestinal and respiratory drugs, food/health supplements and also to speed up expansion in the Asia Pacific market.


Akses Wahanariau.com Via Mobile m.Wahanariau.com
Untuk Berbagi Berita / Informasi / Peristiwa
Silahkan SMS ke nomor HP : 085271472010
atau email ke alamat : [email protected]
Harap camtumkan detail data diri Anda
Pengutipan Berita dan Foto, Cantumkan Wahanariau.com Sebagai Sumber Tanpa Penyingkatan
TULIS KOMENTAR
BERITA TERKAIT
Selasa,25 Juni 2019 - 20:02:24 WIB

Tahun 2019, Pendapatan Jacobson Pharma Meningkat 10,1 Persen

CINA – 25 Juni 2019 – Perusahaan R&D bidang pengembangan dan penjualan obat-oba

Kamis,22 November 2018 - 01:20:44 WIB

Jacobson Pharma Announces FY2019 Interim Results

Profit from Operations Leapt by 40.7% to HK$158.6 Million Declares Interim Dividend of HK1

Jumat,03 Mei 2019 - 02:55:23 WIB

Jacobson Pharma Issues Positive Profit Alert

Expects to Record Over 20% Increase in Profit Attributable to Shareholders CHINA - 2 May 2019

BERITA LAINNYA
Kamis,07 November 2019 - 15:15:18 WIB

Kuehne + Nagel Launches New Airfreight Perishable Hub in New Zealand

One of the world's leading perishable logistics providers further expands its global network

Kamis,07 November 2019 - 15:12:12 WIB

New Economic Impact Study Shows that Singapore SMEs Financed by SME Financing Platform Validus Capital Contributed Over S$400 Million in GDP in 2018

Validus Capital (Validus) is filling a critical financing gap for SMEs across industries to fuel S

Kamis,07 November 2019 - 15:08:27 WIB

Shopmatic Brings a Volley of Power-packed Features, Aiding Merchant Discoverability & Success

Launches POS feature to enable omnichannel sales Joins forces with OnlineSales.ai to help custome

BERGABUNG DI SINI
KABAR POPULER
IKUTI BERITA KAMI